

UROLIFT 2 ATC™

Advanced Tissue Control

**DELIVERING CONFIDENCE.
IMPLANTING OUTCOMES.**

Designed for all prostate types.*

Innovating on the #1 chosen minimally invasive treatment for BPH in the U.S.,¹ the UroLift™ 2 ATC System is designed to make it easier for urologists to treat more patients with the UroLift System, with confidence.²



TM

VISIT US AT AUA2024 BOOTH #1223

Join us to see how you and your patients could benefit from the #1 BPH MIST in the U.S. chosen by urologists and patients alike.¹

VISIT US AT AUA2024 BOOTH #1223

- Get hands-on experience with the latest UroLift™ System technology in our simulator room
- Meet with our experts for product demonstrations
- Learn how the UroLift System:
 - Is an early treatment alternative to BPH medications³
 - Provides superior patient experience** among leading BPH procedures⁴⁻⁶
 - Is the only BPH MIST with consistent durability in real world and clinical trials^{3,4}

ADVANCING BPH CARE: ROLE OF APPs IN A NEW ERA OF DIAGNOSIS AND TREATMENT

Sunday, May 5 • 6:45 to 7:30 A.M.

Hemisfair Ballroom 2

Speakers: Matt Ashley, MD and Erin Dwyer, MSN, FNP-C***

GAIN INSIGHTS FROM THE LATEST DATA

The Early Patient Experience Following Treatment with PUL and WVTT, Two Contemporary MISTs for BPH: Preliminary Results from the CLEAR Study

Presented by: Claus Roehrborn, MD***

A US Healthcare Claims Analysis Reveals Post-surgery Medication Use through 5 years is Similar Between PUL, TURP and GreenLight

Presented by: Steven Kaplan, MD****

Preliminary RCT Analysis of Minimally Invasive Surgery vs. Medication in the Initial Treatment of BPH-Associated LUTS

Presented by: Claus Roehrborn, MD***

Total Procedural Context is Crucial in Understanding BPH Treatment Device Safety in the FDA's MAUDE Database

Presented by: Rajesh Shinghal, MD***

Real-World Analysis of Hospitalizations and Emergency Department Visits Following Surgical Treatments for Benign Prostatic Hyperplasia (BPH) Reveal Distinctions Between Minimally Invasive and Traditional Surgery

Presented by: Steven Kaplan, MD****



Scan to learn more

Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.⁷ Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

*Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence, urethral conditions that prevent device insertion, or a prostate volume greater than 100cc.

**Patient experience defined as a combination of rapid symptom relief, low risk profile, and preservation of sexual function.

***Matt Ashley is an employee of Teleflex. Erin Dwyer, Claus Roehrborn, and Rajesh Shinghal are paid consultants of Teleflex.

**** Steven Kaplan is not a paid consultant of Teleflex.

1. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness.;

2. Data on file; 3. Roehrborn, Can J Urol 2017; 4. Kaplan, Prostate Cancer Prostatic Dis 2023; 5. Gratzke, BJU Int 2016; 6. Tutrone, Can J Urol 2020; 7. Roehrborn, J Urology 2013

Teleflex, the Teleflex logo, UroLift, UroLift ATC, and the UroLift logo are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

©2024 Teleflex Incorporated. All rights reserved. MAC02853-01 Rev A

TeleflexTM
INTERVENTIONAL UROLOGY